A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Pevonedistat in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 13 Nov 2018 Status changed from active, no longer recruiting to completed.
- 19 Oct 2018 Planned End Date changed from 30 Sep 2018 to 5 Nov 2018.
- 25 May 2018 Planned End Date changed from 3 May 2018 to 30 Sep 2018.